Pharmaceutical Executive-12-01-2019

Renewed education efforts by employers, however, are slowly helping them take back decision-making reins in their engagements with pharma.

Lundbeck executive Taj Bhardwaj talks about the differing mindsets necessary to lead local and global-level market access strategy in pharma-and how his current company is committed to stay in the fight to advance new treatments and break down stigmas in mental health.

Exploring the roadmap for US-based, R&D-focused biopharma companies seeking to successfully penetrate product markets and reach patients in Europe.

Industry working group identifies the value characteristics that may, collectively, become part of a shared approach to valuing pharmaceutical treatments.

With so many different rationales for drug pricing and “value” continuing to feed the debate, the market access function in healthcare must clearly tackle these issues-but at what cost to the patient?

The industry’s quest to get a handle on the cost-shift implications of these new programs and the risks for patient access and pharma’s bottom line.

Sponsors developed important new therapies amidst ongoing concerns over drug quality and costs.

European Commission working group is looking closely at marketing obligations for centrally authorized products.

Gauging physician awareness of nucleic acid-based therapies.

Click the title above to open the Pharmaceutical Executive December 2019 issue in an interactive PDF format.

More than two years since the devastation inflicted by Hurricane Maria, Puerto Rico’s supply of medical products has remained largely uninterrupted, debunking common misconceptions at the time and maintaining the island’s standing as one of the most attractive life sciences manufacturing hubs.